Mark Altmeyer - Founder and Chief Executive Officer of Arvelle Therapeutics

Mark has 35+ years of experience leading successful drug development and commercialization efforts as a pharmaceutical executive. During his tenure as CEO of Arvelle, the company was acquired by Angelini Pharma in Feb 2021.

He was previously President and Chief Commercial Officer at Axovant Sciences. Prior to that Mark was Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013.

Mark  currently is on multiple boards (Novaremed, AM Pharma and Clarion) and serves as an advisor on other companies (AIM Pharma and Orange Grove Bio).  

Earlier in his career, Mark held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit.
Mark received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.